Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Imidocarb is a urea derivative and small molecule antiprotozoal agent used in veterinary medicine. It is primarily indicated for the treatment of infections caused by protozoa such as Babesia (babesiosis), Anaplasma in cattle, and Ehrlichia canis in dogs. Its mechanism of action is not fully understood but proposed mechanisms include inhibition of acetylcholinesterase (anticholinergic effect), interference with polyamine production/utilization in Trypanosoma brucei, and prevention of inositol entry into erythrocytes infected with Babesia ovis. Imidocarb is administered as the dipropionate salt via intramuscular or subcutaneous injection[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on imidocarb.